Literature DB >> 8414840

Recombinant erythropoietin in anemia of prematurity: five years later.

K Shannon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8414840

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  4 in total

1.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

2.  Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease.

Authors:  G Griffiths; R Lall; S Chatfield; A Short; P Mackay; P Williamson; J Brown; M I Levene
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

Review 3.  Anaemia of prematurity. Epidemiology, management and costs.

Authors:  M P Meyer
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

4.  Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.

Authors:  V P Carnielli; R Da Riol; G Montini
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.